4.7 Review

Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer

Journal

NATURE REVIEWS IMMUNOLOGY
Volume 18, Issue 12, Pages 773-789

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41577-018-0066-7

Keywords

-

Categories

Funding

  1. Arthritis Research UK
  2. GlaxoSmithKline
  3. Kidney Research UK
  4. Systems Immunity University Research Institute at Cardiff University
  5. National Health and Medical Research Council of Australia (NHMRC)
  6. NHMRC
  7. Cancer Council of Victoria
  8. Avner Pancreatic Cancer Foundation
  9. Victorian State Government

Ask authors/readers for more resources

The IL-6 family of cytokines consists of IL-6, IL-11, IL-27, IL-31, oncostatin M (OSM), leukaemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotrophin 1 (CT-1) and cardiotrophin-like cytokine factor 1 (CLCF1). Membership of this cytokine family is defined by usage of common beta-receptor signalling subunits, which activate various intracellular signalling pathways. Each IL-6 family member elicits responses essential to the physiological control of immune homeostasis, haematopoiesis, inflammation, development and metabolism. Accordingly, distortion of these cytokine activities often promotes chronic disease and cancer; the pathological importance of this is exemplified by the successful treatment of certain autoimmune conditions with drugs that target the IL-6 pathway. Here, we discuss the emerging roles for IL-6 family members in infection, chronic inflammation, autoimmunity and cancer and review therapeutic strategies designed to manipulate these cytokines in disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available